Record Company Revenue (RBR) and Multi-Year Growth
Fourth quarter RBR of $432.3M, up 11.3% year-over-year; full year RBR of $1.66B, up 11.9% versus 2024. 2025 marked record RBR and the fifth consecutive year of RBR growth.
Adjusted EBITDA Margin Expansion
Adjusted EBITDA margin of 15.7% in Q4 2025 (vs. 14.6% in Q4 2024) and 14.3% for full year 2025 (vs. 13.5% in 2024). Company has expanded adjusted EBITDA margins by ~400 basis points since 2020.
Record Adjusted Diluted EPS
Record adjusted diluted EPS of $7.83 for full year 2025, a 21% increase over 2024; Q4 2025 adjusted EPS of $2.17 versus $1.90 in Q4 2024.
Commercial Segment Surge
Commercial segment RBR grew 36.6% in Q4 2025 to $91.9M and 27.2% for the full year to $325.1M. Organic Q4 commercial growth excluding acquisitions was +9.1%. Commercial now represents ~20% of total RBR.
Healthcare Segment Strength and Momentum
Healthcare delivered record full-year RBR of $837.5M, up 10.7% vs. 2024; Q4 Healthcare RBR +9.6% to $221.7M. Bookings in H2 2025 increased more than 20% vs. H2 2024 and sales conversions continued into January 2026.
Digital and AI Adoption Driving Growth
Digital capability represented 41% of company RBR in 2025. Digital RBR grew 10% for the year; data management/analytics/AI RBR grew over 40% year-over-year. Company has deployed over 100 AI and automation solutions and announced strategic AI partnerships.
Strong Backlog, Pipeline and 2026 Guidance
Management reports the strongest hard backlog coverage of initial annual RBR guidance in five years and near-record pipeline. 2026 guidance: RBR $1.78B–$1.86B (midpoint ≈ +9.5% YoY), adjusted EBITDA margin 14.5%–15% (≈ +50 bps vs 2025 midpoint), and adjusted EPS $8.35–$9.15 (midpoint ≈ +12% YoY).
Cash Generation and Share Repurchases
2025 operating cash flow $193.4M and free cash flow $162.3M. Used $166M for share repurchases in 2025 (~1.2M shares, 6.6% of outstanding), $70M repurchased in Q1 2026, and Board authorized an additional $200M (≈ $229M remaining). Net debt decreased versus Q3 2025 by $100.6M; leverage ~1.9x adjusted EBITDA as of 12/31/25.